| scholarly article | Q13442814 |
| P50 | author | Katherine A. High | Q41502889 |
| Stephen R Russell | Q44883012 | ||
| Arlene Drack | Q56529441 | ||
| Elliott H Sohn | Q58398731 | ||
| Edwin M. Stone | Q37381855 | ||
| Chris A. Johnson | Q37831129 | ||
| P2093 | author name string | Dina Gewaily | |
| Bart P Leroy | |||
| Janet Wittes | |||
| Francesca Simonelli | |||
| Jean Bennett | |||
| Vinit B Mahajan | |||
| Daniel C Chung | |||
| Okan Elci | |||
| Julia A Haller | |||
| Albert M Maguire | |||
| J Fraser Wright | |||
| Xiaosong Zhu | |||
| Wanda Pfeifer | |||
| Leslie Raffini | |||
| Lindsey A George | |||
| F Parker Hudson | |||
| Zi-Fan Yu | |||
| Maria Davis | |||
| Laura Dingfield | |||
| Kathleen A Marshall | |||
| Dominique Cross | |||
| Sarah McCague | |||
| Michelle Weckmann | |||
| Katie Wachtel | |||
| Amy Tillman | |||
| Hannah Reichert | |||
| Jean Walshire | |||
| Jennifer A Wellman | |||
| Julie Pappas | |||
| Taylor L Kehoe | |||
| P2860 | cites work | Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT). | Q40051827 |
| Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. | Q40736925 | ||
| Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. | Q40787452 | ||
| Gene therapy restores vision in a canine model of childhood blindness | Q43590733 | ||
| Identification of the RPE65 protein in mammalian cone photoreceptors. | Q43974161 | ||
| In utero gene therapy rescues vision in a murine model of congenital blindness | Q44753954 | ||
| Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA. | Q45865415 | ||
| Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation | Q46553714 | ||
| Novel mobility test to assess functional vision in patients with inherited retinal dystrophies | Q48143937 | ||
| Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. | Q52532886 | ||
| Visual acuity measurements | Q79797879 | ||
| Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial | Q87404711 | ||
| Omics in Ophthalmology: Advances in Genomics and Precision Medicine for Leber Congenital Amaurosis and Age-Related Macular Degeneration | Q89054563 | ||
| Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial | Q24608049 | ||
| Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration | Q24627838 | ||
| The human visual cortex responds to gene therapy-mediated recovery of retinal function | Q24629697 | ||
| Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 | ||
| Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis | Q24685618 | ||
| Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey | Q27329160 | ||
| RPE65 is present in human green/red cones and promotes photopigment regeneration in an in vitro cone cell model | Q28255485 | ||
| Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial | Q28262431 | ||
| Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark | Q28270488 | ||
| Effect of gene therapy on visual function in Leber's congenital amaurosis | Q28277981 | ||
| Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) | Q28551677 | ||
| Identification of RDH10, an All-trans Retinol Dehydrogenase, in Retinal Muller Cells | Q28568047 | ||
| Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer | Q33315634 | ||
| A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients | Q33601217 | ||
| Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. | Q34015881 | ||
| Human photoreceptor topography | Q34034782 | ||
| Improvement and decline in vision with gene therapy in childhood blindness. | Q34474831 | ||
| Vector platforms for gene therapy of inherited retinopathies. | Q34561531 | ||
| Long-term effect of gene therapy on Leber's congenital amaurosis | Q35836291 | ||
| Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis | Q36198173 | ||
| Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement | Q36598421 | ||
| Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness | Q36825024 | ||
| Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2 | Q36906324 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| Transient transfection methods for clinical adeno-associated viral vector production | Q37479802 | ||
| Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). | Q37656641 | ||
| Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. | Q37701838 | ||
| Manufacturing and regulatory strategies for clinical AAV2-hRPE65. | Q37780248 | ||
| Cone Health and Retinoids | Q38574403 | ||
| P433 | issue | 10097 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase III clinical trial | Q42824827 |
| P304 | page(s) | 849-860 | |
| P577 | publication date | 2017-07-14 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial | |
| P478 | volume | 390 |
| Q92821590 | A 2-Year Longitudinal Study of Normal Cone Photoreceptor Density |
| Q90342146 | A Cross-Sectional and Longitudinal Study of Retinal Sensitivity in RPE65-Associated Leber Congenital Amaurosis |
| Q92302063 | A Mini Review: Moving iPSC-Derived Retinal Subtypes Forward for Clinical Applications for Retinal Degenerative Diseases |
| Q98177383 | A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome |
| Q55620891 | A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. |
| Q90716949 | A novel, wearable, electronic visual aid to assist those with reduced peripheral vision |
| Q94562305 | A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing |
| Q91824404 | A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism |
| Q90732125 | AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice |
| Q92876148 | AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer |
| Q90593924 | AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity |
| Q92666846 | AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice |
| Q64064271 | Accuracy of a deep convolutional neural network in detection of retinitis pigmentosa on ultrawide-field images |
| Q59354464 | Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls |
| Q59968531 | Acoustically targeted chemogenetics for the non-invasive control of neural circuits |
| Q58594108 | Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments |
| Q92345084 | Adeno-Associated Viral Vectors in Neuroscience Research |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q64088191 | Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial |
| Q59356408 | Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort |
| Q90298681 | Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa |
| Q59349320 | Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital Blindness |
| Q58080789 | An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4-/- mice |
| Q89604802 | An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK |
| Q50093390 | An ode to gene edits that prevent deafness |
| Q57022663 | Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration |
| Q98159549 | Assessment of AAV Dual Vector Safety in theAbca4 -/- Mouse Model of Stargardt Disease |
| Q90656139 | Attenuation of Inherited and Acquired Retinal Degeneration Progression with Gene-based Techniques |
| Q52728747 | BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. |
| Q57296603 | Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia |
| Q49823719 | Biosafety in Handling Gene Transfer Vectors |
| Q90945769 | Breaking and Sealing Barriers in Retinal Gene Therapy |
| Q92824352 | C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa |
| Q92558825 | CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials |
| Q104073578 | COG5 variants lead to complex early onset retinal degeneration, upregulation of PERK and DNA damage |
| Q64108207 | CRISPR Activation Enhances Potency of AAV Vectors Driven by Tissue-Specific Promoters |
| Q57171979 | CRISPR/Cas9 genome surgery for retinal diseases |
| Q64232175 | Cell Therapy for Retinal Dystrophies: From Cell Suspension Formulation to Complex Retinal Tissue Bioengineering |
| Q93051388 | Characterizing variants of unknown significance in rhodopsin: A functional genomics approach |
| Q104076002 | Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy |
| Q64230434 | Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1-9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons |
| Q90724417 | Contribution of noncoding pathogenic variants to RPGRIP1-mediated inherited retinal degeneration |
| Q91986136 | Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease |
| Q59354563 | Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration |
| Q104289829 | Current Clinical Applications of in vivo Gene Therapy with AAVs |
| Q58595420 | Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward |
| Q92539077 | Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management |
| Q92643998 | Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses |
| Q91524508 | Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine |
| Q90681476 | Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders |
| Q89882245 | Disease asymmetry and hyperautofluorescent ring shape in retinitis pigmentosa patients |
| Q98613396 | Drug Tissue Distribution of TUDCA From a Biodegradable Suprachoroidal Implant versus Intravitreal or Systemic Delivery in the Pig Model |
| Q103029582 | EYS is a major gene involved in retinitis pigmentosa in Japan: genetic landscapes revealed by stepwise genetic screening |
| Q55242203 | Early onset flecked retinal dystrophy associated with new compound heterozygous RPE65 variants. |
| Q90596716 | Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect |
| Q90437090 | Effects of deficiency in the RLBP1-encoded visual cycle protein CRALBP on visual dysfunction in humans and mice |
| Q57164418 | Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector |
| Q64913270 | Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65. |
| Q92301663 | Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease |
| Q57282715 | Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier |
| Q91910378 | Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues |
| Q64041271 | Estimation of impact of mediated inherited retinal disease on quality of life and the potential benefits of gene therapy |
| Q60907573 | Evaluation of AAV-DJ vector for retinal gene therapy |
| Q57803544 | Exposure to wild-type AAV drives distinct capsid immunity profiles in humans |
| Q45873391 | FDA advisers back gene therapy for rare form of blindness |
| Q91259657 | Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection |
| Q90335415 | Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction |
| Q91740114 | Four technologies that could transform the treatment of blindness |
| Q92301708 | Functional Assessment of Vision Restoration |
| Q90567439 | Functional Genomics of the Retina to Elucidate its Construction and Deconstruction |
| Q58600532 | GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges |
| Q91557396 | GPR108 Is a Highly Conserved AAV Entry Factor |
| Q59807311 | Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic |
| Q92937453 | Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9 |
| Q91734216 | Gene Therapy for Neurologic Disease: A Neurosurgical Review |
| Q100512500 | Gene therapy and gene correction: targets, progress, and challenges for treating human diseases |
| Q54977409 | Gene therapy and genome surgery in the retina. |
| Q45869784 | Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3. |
| Q91972798 | Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model |
| Q91341548 | Gene therapy for retinal dystrophy |
| Q90399579 | Generation and Characterization of Induced Pluripotent Stem Cells and Retinal Organoids From a Leber's Congenital Amaurosis Patient With Novel RPE65 Mutations |
| Q92276489 | Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa |
| Q92464626 | Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles |
| Q52429662 | Genome Surgery and Gene Therapy in Retinal Disorders. |
| Q55000684 | Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy. |
| Q93016526 | Has retinal gene therapy come of age? From bench to bedside and back to bench |
| Q59355428 | Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation |
| Q58779571 | Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System |
| Q57823807 | Human Cardiac Gene Therapy |
| Q64228294 | Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial |
| Q89574758 | Improved cell-specificity of adeno-associated viral vectors for medullary thyroid carcinoma using calcitonin gene regulatory elements |
| Q91555334 | In vivo biodistribution analysis of transmission competent and defective RNA virus-based episomal vector |
| Q92345097 | Inclusion of PF68 Surfactant Improves Stability of rAAV Titer when Passed through a Surgical Device Used in Retinal Gene Therapy |
| Q90405906 | Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps |
| Q89867366 | Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR |
| Q89868009 | Intraocular Lens Dislocation into the Anterior Chamber because of Repeated Eye-Poking in a Patient with Leber's Congenital Amaurosis |
| Q94595322 | Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery |
| Q91973145 | Investigation and Restoration of BEST1 Activity in Patient-derived RPEs with Dominant Mutations |
| Q91528024 | KIT ligand protects against both light-induced and genetic photoreceptor degeneration |
| Q90152961 | Leber Congenital Amaurosis (LCA): Potential for Improvement of Vision |
| Q96591115 | Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B |
| Q90661184 | Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy |
| Q59505636 | Low vision services: a practical guide for the clinician |
| Q89975685 | Metabolic and Redox Signaling of the Nucleoredoxin-Like-1 Gene for the Treatment of Genetic Retinal Diseases |
| Q98292037 | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
| Q89932125 | MicroRNA-based recombinant AAV vector assembly improves efficiency of suicide gene transfer in a murine model of lymphoma |
| Q64079147 | Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy |
| Q90704145 | Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity |
| Q89115884 | NAD+ and sirtuins in retinal degenerative diseases: A look at future therapies |
| Q50065340 | Negative regulators that mediate ocular immune privilege |
| Q56334374 | Neuraminidase Mediated Desialylation Augments AAV9 Mediated Gene Expression in Skeletal Muscle |
| Q89920527 | Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues |
| Q57065785 | Non-Viral Delivery To Enable Genome Editing |
| Q90700521 | Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles |
| Q100454957 | Novel 199 base pair NEFH promoter drives expression in retinal ganglion cells |
| Q99711158 | Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing |
| Q48143937 | Novel mobility test to assess functional vision in patients with inherited retinal dystrophies |
| Q64239571 | Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa |
| Q89983887 | Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa |
| Q92146688 | Ocular gene therapy for choroideremia: clinical trials and future perspectives |
| Q90027776 | Optimizing Donor Cellular Dissociation and Subretinal Injection Parameters for Stem Cell-Based Treatments |
| Q91554982 | Optogenetic restoration of retinal ganglion cell activity in the living primate |
| Q57296070 | PROGRESSION OF SCOTOPIC SINGLE-FLASH ELECTRORETINOGRAPHY IN THE STAGES OF CAPN5 VITREORETINOPATHY |
| Q89889178 | Patient-reported outcome measures in inherited retinal degeneration gene therapy trials |
| Q97885050 | Perspectives on Gene Therapy: Choroideremia Represents a Challenging Model for the Treatment of Other Inherited Retinal Degenerations |
| Q60932114 | Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye |
| Q89516662 | Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477G mutation in RPE65 |
| Q58792694 | Precision medicine and clinical ophthalmology |
| Q90355187 | Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration |
| Q52664653 | Presentation of TRPM1-Associated Congenital Stationary Night Blindness in Children. |
| Q55039934 | Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy. |
| Q89456228 | Progress in the development of novel therapies for choroideremia |
| Q55261908 | Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. |
| Q93005878 | RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences |
| Q92301653 | RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies |
| Q89510411 | RPGR-Associated Dystrophies: Clinical, Genetic, and Histopathological Features |
| Q98292027 | Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease |
| Q91707074 | Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? |
| Q92122134 | Rescue of Rod Synapses by Induction of Cav Alpha 1F in the Mature Cav1.4 Knock-Out Mouse Retina |
| Q92283322 | Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA |
| Q59066985 | Restoring vision |
| Q57039862 | Retained Plasticity and Substantial Recovery of Rod-Mediated Visual Acuity at the Visual Cortex in Blind Adult Mice with Retinal Dystrophy |
| Q90340334 | Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat |
| Q92163156 | Retinal Gene Distribution and Functionality Implicated in Inherited Retinal Degenerations Can Reveal Disease-Relevant Pathways for Pharmacologic Intervention |
| Q96610123 | Retinal gene therapy: an eye-opener of the 21st century |
| Q94466892 | Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial |
| Q91259654 | Safety and efficacy evaluations of an adeno-associated virus variant for preparing IL10-secreting human neural stem cell-based therapeutics |
| Q99614977 | Sensing through Non-Sensing Ocular Ion Channels |
| Q64081490 | Seven novel variants expand the spectrum of related Leber congenital amaurosis in the Chinese population |
| Q48538458 | Severe Loss of Tritan Color Discrimination in RPE65 Associated Leber Congenital Amaurosis |
| Q90346056 | Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses |
| Q96126887 | Short-Wavelength and Near-Infrared Autofluorescence in Patients with Deficiencies of the Visual Cycle and Phototransduction |
| Q91622762 | Soluble CX3CL1 gene therapy improves cone survival and function in mouse models of retinitis pigmentosa |
| Q52586106 | Special Issue Introduction: Inherited Retinal Disease: Novel Candidate Genes, Genotype-Phenotype Correlations, and Inheritance Models. |
| Q55387849 | Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA. |
| Q57801131 | Structural biology of 11-retinaldehyde production in the classical visual cycle |
| Q83232387 | Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR |
| Q89704563 | Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates |
| Q57039821 | Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| Q52584544 | Tapping the RNA world for therapeutics. |
| Q91724148 | Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans |
| Q98205367 | Targeting the photoreceptor cilium for the treatment of retinal diseases |
| Q89621186 | Tetramer-Based Enrichment of Preexisting Anti-AAV8 CD8+ T Cells in Human Donors Allows the Detection of a TEMRA Subpopulation |
| Q90093984 | The detection of trans gene fragments of hEPO in gene doping model mice by Taqman qPCR assay |
| Q89720736 | The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis |
| Q45874106 | The pigmented epithelium, a bright partner against photoreceptor degeneration |
| Q60923268 | The potential of small molecule brain-derived neurotrophic factor: mimetics to treat inherited retinal degeneration |
| Q90093639 | The special considerations of gene therapy for mitochondrial diseases |
| Q78176806 | The use of nonhuman primates in studies of noise injury and treatment. |
| Q61815427 | Trans-ocular Electric Current Enhances AAV-Mediated Retinal Gene Transduction after Intravitreal Vector Administration |
| Q57139324 | Transfection by cationic gemini lipids and surfactants |
| Q94465899 | Tunneling Nanotubes and the Eye: Intercellular Communication and Implications for Ocular Health and Disease |
| Q102075252 | Turning genes into medicines-what have we learned from gene therapy drug development in the past decade? |
| Q90455536 | Use of Virtual Reality Simulation to Identify Vision-Related Disability in Patients With Glaucoma |
| Q90453825 | Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy |
| Q99581468 | Validation of a Vision-Guided Mobility Assessment for RPE65-Associated Retinal Dystrophy |
| Q101564121 | Whole exome sequencing and homozygosity mapping reveals genetic defects in consanguineous Iranian families with inherited retinal dystrophies |
| Q92342630 | Wide-field fundus autofluorescence imaging in patients with hereditary retinal degeneration: a literature review |
| Q90258684 | [Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the Professional Association of German Ophthalmologists (BVA) on the therapeutic use of voretigene neparvovec-rzyl (Luxturna™) in ophthalmology : Situation J |
| Q90743118 | [What's new in research?] |
Search more.